Following the manufacture of the biopharmaceutical drug substance comes the manufacture of the drug product—the packaged medicine to be released for patient administration. Since biopharmaceutical drug products are primarily administered parenterally (e.g., injection, infusion), they must be sterile; therefore, the drug product manufacturing process requires strict adherence to cGMPs, appropriate and adequate aseptic processing, correct selection of the container closure, and tight control of the filling process parameters. The focus of this chapter is on drug product manufacturing for both protein-based biopharmaceuticals (recombinant proteins and monoclonal antibodies) and gene-based biopharmaceuticals (viral vectors, non-viral vectors, genetically modified patient cells). The three main process stages for the drug product manufacture are discussed in this chapter: (1) compounding (including either formulation of the drug substance or formulation adjustment of the previously formulated drug substance), (2) preparation of the sterile compounded product solution, and (3) aseptic filling of the sterile compounded drug into the sterile container closure system. Application, where appropriate, for the minimum CMC regulatory compliance continuum risk-based approach will be discussed. At times, the container-closure system is also a delivery device making the biopharmaceutical drug product a combination product, which will be discussed here.